2021
NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS
Jin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.Peer-Reviewed Original ResearchSphenoid wing meningiomaSpheno-orbital meningiomasBony involvementTRAF7 mutationsTumor invasionGenomic subgroupsPre-operative clinical featuresYale-New Haven HospitalAdditional clinical variablesSubset of tumorsPre-operative predictionLogistic regression modelsWhole-exome sequencingClinical featuresClinical variablesGrade IIPredictive logistic regression modelRecurrence patternsMolecular subtypesClinical implicationsExome sequencingHyperostosisMeningiomasTumorsGenomic drivers
2020
LGG-09. CORRELATING GENETIC SIGNATURE OF PILOMYXOID ASTROCYTOMAS AND PILOCYTIC ASTROCYTOMAS WITH QUALITATIVE AND QUANTITATIVE MR IMAGING CHARACTERISTICS
Fadel S, Omay Z, Darbinyan A, Bronen R, Fulbright R, Mahajan A, Aboian M. LGG-09. CORRELATING GENETIC SIGNATURE OF PILOMYXOID ASTROCYTOMAS AND PILOCYTIC ASTROCYTOMAS WITH QUALITATIVE AND QUANTITATIVE MR IMAGING CHARACTERISTICS. Neuro-Oncology 2020, 22: iii367-iii368. PMCID: PMC7715503, DOI: 10.1093/neuonc/noaa222.392.Peer-Reviewed Original ResearchKIAA1549-BRAF fusionBRAF V600E mutationWhole-exome sequencingBRAF-wildtypePilocytic astrocytomaWildtype tumorsV600E mutationImaging characteristicsExome sequencingAtypical imaging featuresMR imaging characteristicsMyxoid featuresPediatric patientsPilomyxoid astrocytomaIntraventricular extensionImaging featuresIntratumoral hemorrhageMRI characteristicsGermline sequencingAtypical featuresT1 intensityTumor localizationWildtype BRAFKIAA1549-BRAFPA correlates
2019
HOUT-03. CLINICAL OUTCOMES OF PATIENTS WITH VESTIBULAR SCHWANNOMAS: THE RELEVANCE OF TUMOR SIZE AND RECURRENCE
Zhao A, Fomchenko E, Tyrtova E, Huttner A, Zhang Y, Fulbright R, Erson-Omay E, Jin L, Moliterno J. HOUT-03. CLINICAL OUTCOMES OF PATIENTS WITH VESTIBULAR SCHWANNOMAS: THE RELEVANCE OF TUMOR SIZE AND RECURRENCE. Neuro-Oncology 2019, 21: vi112-vi112. PMCID: PMC6846905, DOI: 10.1093/neuonc/noz175.468.Peer-Reviewed Original ResearchVestibular schwannomaSurgical resectionClinical outcomesTumor sizeLarge tumorsExact testPre-operative tumor sizeSignificant associationProgression-free survival timeMost vestibular schwannomasFacial nerve functionPost-operative complicationsBetter clinical outcomesLow recurrence rateClinical outcome dataBilateral vestibular schwannomasDifferent surgical approachesFisher's exact testSlow growth potentialIntra-tumoral hemorrhageWhole-exome sequencingNerve functionRecurrence rateVS tumorsSurgical approach
2018
P04.60 Genomic profile of tumorigenesis in a patient with Turcot syndrome
Karschnia P, Erson-Omay E, Huttner A, Fulbright R, Günel M, Baehring J. P04.60 Genomic profile of tumorigenesis in a patient with Turcot syndrome. Neuro-Oncology 2018, 20: iii293-iii293. PMCID: PMC6143975, DOI: 10.1093/neuonc/noy139.294.Peer-Reviewed Original ResearchWhole-exome sequencingEndometrial carcinomaTurcot syndromeBrain tumorsMicrosatellite instabilityMMR genesSecond hitSomatic missense mutationsMissense mutationsLeft frontal tumorPrimary brain tumorsPatient's brain tumorMismatch repair deficiencyMMR-deficient tumorsExpression of MSH6Heterozygous germline mutationsHeterozygous germline missense mutationRight hemiparesisSubtotal resectionUterine adenocarcinomaMetachronous tumorsFrontal tumorGermline missense mutationAbdominal tumorsFamily history